Transgenic Tau Models

Test potential therapeutics for Alzheimer’s disease and other Tauopathies in mouse models with Tau deposition and the downstream pathological events

Home » Neurology Research Models and Services  » Alzheimer’s models and services » Alzheimer’s models – Transgenic Tau Models
The histopathological hallmarks of Alzheimer’s disease (AD) are extracellular plaques composed of amyloid beta (Aβ) and intracellular inclusions of the protein Tau (neurofibrillary tangles). Tau is encoded by the microtubule-associated protein tau (MAPT) gene. Tau pathology in AD and other Tauopathies such as frontotemporal dementia (FTD) is strongly associated with neurodegeneration and clinical symptoms. 

Models overexpressing human Tau with disease associated MAPT mutations display abundant tau pathology, neuroinflammation, neurodegeneration, and behavioural impairments; making them ideal models to test therapeutic interventions for AD and other tauopathies.

InnoSer offers unique behavioural research services using several in vivo AD models, including a range of transgenic tauopathy models. Mouse models recapitulating the Tau pathology are suitable for testing compound for AD, but also a range of other Tauopathies (FTD, frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, Pick’s disease). 

InnoSer offers expert guidance and collaborative approach on selecting the best model for your research, as the models we offer present varying degrees of neurofibrillary tangles, neuroinflammation, neurodegeneration, and behavioural deficits.  

Transgenic amyloid models that InnoSer offers:

  • P301S (PS19)
  • TauP301L (JNPL3)
  • Tau seeding models (e.g., in PS19, hTau) 

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key readouts

Test the efficacy of your treatments in the following behavioural tests:

Test the efficacy of your treatments with the following biological readouts: 

  • MSD: Plasma, CSF, and brain (pTau, cytokines, NF-L) 
  • (Digital) histopathology 
  • Immunohistochemistry (e.g.,  pTau, neuroinflammation, neurodegeneration) 
  • Immunofluorescence and FISH 

Related Alzheimer’s disease model options

Neurology Platform Overview

Highly relevant neurology models to facilitate preclinical drug development

Transgenic Amyloid Models

InnoSer offers preclinical research services with several different transgenic amyloid models, which recapitulate the plaque pathology of AD.

Tau Seeding Model

InnoSer uses an AD brain extract injection model, providing unique preclinical services with a translational model of Tau pathology seeding and spreading.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know